Macrophage Migration Inhibitory Factor - 173 G/C Polymorphism is Associated With The Age of Onset and Insight in Schizophrenia in the Turkish Population

References

• Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry. 2013;73(10):951–966.
   PubMed Web of Science ®Google Scholar
• Aytac HM, Ozdilli K, Tuncel FC, et al. Tumor necrosis factor-alpha (TNF-α)− 238 G/A polymorphism is associated with the treatment resistance and attempted suicide in schizophrenia. Immunol Invest. 2020;1–13. DOI:https://doi.org/10.1080/08820139.2020.1832115
   Google Scholar
• Erkmen T, Şahin C, Arıcıoğlu F. Şizofreni’de İnflamatuvar Mekanizmaların Yeri. J Marmara Univ Inst Health Sci. 2015;5:2.
   Google Scholar
• R. B. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol. 2013;33(1):72–78.
   Google Scholar
• Xu L, Li Y, Sun H, et al. Current developments of macrophage migration inhibitory factor (MIF) inhibitors. Drug Discov Today. 2013;18(11–12):592–600. .
   PubMed Web of Science ®Google Scholar
• Bloom J, Al-Abed Y. MIF: mood improving/inhibiting factor? J Neuroinflammation. 2014;11(1):11.
   PubMedGoogle Scholar
• Spitzer RL, Williams JB, Gibbon M, et al. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624–629.
   PubMed Web of Science ®Google Scholar
• Özkürkçügil A, Aydemir Ö, Yıldız M, Esen Danacı A, Köroğlu IV E. DSM-IV Eksen I bozuklukları için yapılandırılmış klinik görüşmenin Türkçe’ye uyarlanması ve güvenilirlik çalışması. İlaç ve tedavi dergisi. 1999;12(4):233–236.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Kostakoğlu A, Batur S, Tiryaki A, et al. Pozitif ve negatif sendrom ölçeğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi. 1999;14(44):23–32.
   Web of Science ®Google Scholar
• David AS. Insight and psychosis. Br J Psychiatry. 1990;156:798–808.
   PubMed Web of Science ®Google Scholar
• Arslan SGKB, Karakılıç H. İçgörünün üç bileşenini değerlendirme ölçeği:güvenilirlik ve geçerlik çalışması. Türkiye’de Psikiyatri. 2001;3:17–24.
   Google Scholar
• Guy W. Clinical global impression. Assess Manual Psychopharmacol. 1976;217–222.
   Google Scholar
• Ekşi F, Pehlivan S, Erdoğan MB, et al. MBL2 and MIF gene polymorphisms in cardiovascular patients with atherosclerotic lesions undergoing heart valve replacement. Biotechnol Biotechnol Equip. 2017;31(6):1173–1177. .
   Web of Science ®Google Scholar
• Sekar A, Bialas AR, De Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177. .
   PubMed Web of Science ®Google Scholar
• Okazaki S, Hishimoto A, Otsuka I, et al. Increased serum levels and promoter polymorphisms of macrophage migration inhibitory factor in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;83:33–41.
   PubMed Web of Science ®Google Scholar
• Chan MK, Krebs M, Cox D, et al. Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl Psychiatry. 2015;5(7):e601–e. .
   PubMedGoogle Scholar
• Schwarz E, Guest PC, Rahmoune H, et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012;17(5):494–502. .
   PubMed Web of Science ®Google Scholar
• Hiroi N, Takahashi T, Hishimoto A, et al. Copy number variation at 22q11. 2: from rare variants to common mechanisms of developmental neuropsychiatric disorders. Mol Psychiatry. 2013;18(11):1153–1165.
   PubMed Web of Science ®Google Scholar
• de la Fontaine L, Schwarz MJ, Riedel M, et al. Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms. Psychiatry Res. 2006;144(1):39–47.
   PubMed Web of Science ®Google Scholar
• Aytac HM, Oyaci Y, Yazar MS, et al. Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients diagnosed with schizophrenia or bipolar disorder. J Clinic Neurosci. 2020;78:264–268.
   PubMed Web of Science ®Google Scholar
• Fraguas D, Díaz-Caneja CM, Rodríguez-Quiroga A, et al. Oxidative stress and inflammation in early onset first episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2017;20(6):435–444.
   PubMed Web of Science ®Google Scholar
• Castle DJ, Wessely S, Howard R, et al. Schizophrenia with onset at the extremes of adult life. Int J Geriatr Psychiatry. 1997;12(7):712–717.
   PubMed Web of Science ®Google Scholar
• Joseph B, Narayanaswamy JC, Venkatasubramanian G. Insight in schizophrenia: relationship to positive, negative and neurocognitive dimensions. Indian J Psychol Med. 2015;37(1):5–11.
   PubMedGoogle Scholar
• Xavier RM, Vorderstrasse A, Keefe RS, et al. Genetic correlates of insight in schizophrenia. Schizophr Res. 2018;195:290–297.
   PubMed Web of Science ®Google Scholar
• Lysaker PH, Dimaggio G, Buck KD, et al. Poor insight in schizophrenia: links between different forms of metacognition with awareness of symptoms, treatment need, and consequences of illness. Compr Psychiatry. 2011;52(3):253–260.
   PubMed Web of Science ®Google Scholar
• Gillespie AL, Samanaite R, Mill J, et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry. 2017;17(1):12.
   PubMedGoogle Scholar
• Binbay Z, Solmaz M, Kurt E. Tedaviye Dirençli İki Uçlu Bozukluk. J Mood Disord. 2015;5:2.
   Google Scholar
• Pisanu C, Squassina A. Treatment-resistant schizophrenia: insights from genetic studies and machine learning approaches. Front Pharmacol. 2019;10:10.
   PubMed Web of Science ®Google Scholar
• Lahdelma L, Koskimies S. Impact of HLA haplotype on the response to antipsychotic treatment of schizophrenia. Curr Pharmacogenomics. 2004;2(2):149–155.
   Google Scholar
• Morrison MC, Kleemann R. Role of macrophage migration inhibitory factor in obesity, insulin resistance, type 2 diabetes, and associated hepatic co-morbidities: a comprehensive review of human and rodent studies. Front Immunol. 2015;6:308.
   PubMed Web of Science ®Google Scholar
• Cui D, Peng Y, Zhang C, et al. Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy. J Clin Invest. 2018;128(11):4997–5007. .
   PubMed Web of Science ®Google Scholar